Market Closed -
Australian S.E.
02:10:35 2022-08-31 am EDT
|
5-day change
|
1st Jan Change
|
0.04
AUD
|
-4.76%
|
|
-.--%
|
-.--%
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
348.9
|
106.2
|
42.8
|
43.61
|
16.3
|
17.62
|
Enterprise Value (EV)
1 |
335.8
|
70.75
|
23.73
|
29.86
|
10.58
|
10.32
|
P/E ratio
|
-44.8
x
|
-13.5
x
|
-6.03
x
|
-4.04
x
|
-0.62
x
|
-1.61
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6,483
x
|
158
x
|
35.4
x
|
24.2
x
|
8
x
|
11.4
x
|
EV / Revenue
|
6,241
x
|
106
x
|
19.6
x
|
16.6
x
|
5.19
x
|
6.66
x
|
EV / EBITDA
|
-42.5
x
|
-11
x
|
-3.44
x
|
-3.37
x
|
-3.4
x
|
-8.37
x
|
EV / FCF
|
-102
x
|
-7.2
x
|
-1.66
x
|
-13.2
x
|
-7.05
x
|
22.8
x
|
FCF Yield
|
-0.98%
|
-13.9%
|
-60.1%
|
-7.59%
|
-14.2%
|
4.38%
|
Price to Book
|
24.7
x
|
2.55
x
|
1.24
x
|
0.98
x
|
0.9
x
|
2.45
x
|
Nbr of stocks (in thousands)
|
276,873
|
316,997
|
317,047
|
440,547
|
440,547
|
440,547
|
Reference price
2 |
1.260
|
0.3350
|
0.1350
|
0.0990
|
0.0370
|
0.0400
|
Announcement Date
|
9/23/18
|
9/25/19
|
9/29/20
|
8/29/21
|
9/30/22
|
10/26/23
|
Fiscal Period: Juni |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.0538
|
0.6706
|
1.21
|
1.8
|
2.038
|
1.551
|
EBITDA
1 |
-7.911
|
-6.44
|
-6.896
|
-8.847
|
-3.108
|
-1.234
|
EBIT
1 |
-7.942
|
-6.497
|
-6.953
|
-9.506
|
-4.9
|
-1.381
|
Operating Margin
|
-14,758.67%
|
-968.77%
|
-574.43%
|
-528.01%
|
-240.44%
|
-89.05%
|
Earnings before Tax (EBT)
1 |
-7.668
|
-7.649
|
-7.076
|
-10.58
|
-24.94
|
-10.7
|
Net income
1 |
-7.668
|
-7.649
|
-7.076
|
-8.641
|
-26.36
|
-10.92
|
Net margin
|
-14,249.65%
|
-1,140.64%
|
-584.63%
|
-479.98%
|
-1,293.45%
|
-703.9%
|
EPS
2 |
-0.0281
|
-0.0248
|
-0.0224
|
-0.0245
|
-0.0598
|
-0.0248
|
Free Cash Flow
1 |
-3.298
|
-9.825
|
-14.26
|
-2.265
|
-1.501
|
0.4524
|
FCF margin
|
-6,127.59%
|
-1,465.12%
|
-1,177.92%
|
-125.81%
|
-73.67%
|
29.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/23/18
|
9/25/19
|
9/29/20
|
8/29/21
|
9/30/22
|
10/26/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
13
|
35.4
|
19.1
|
13.8
|
5.72
|
7.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-3.3
|
-9.83
|
-14.3
|
-2.27
|
-1.5
|
0.45
|
ROE (net income / shareholders' equity)
|
-52.7%
|
-27.4%
|
-18.5%
|
-26.8%
|
-79.7%
|
-84.5%
|
ROA (Net income/ Total Assets)
|
-32.5%
|
-14.1%
|
-11.1%
|
-14.7%
|
-9.63%
|
-6.7%
|
Assets
1 |
23.57
|
54.24
|
63.78
|
58.6
|
273.6
|
163
|
Book Value Per Share
2 |
0.0500
|
0.1300
|
0.1100
|
0.1000
|
0.0400
|
0.0200
|
Cash Flow per Share
2 |
0.0500
|
0.1100
|
0.0600
|
0.0300
|
0.0100
|
0.0200
|
Capex
1 |
0.14
|
7.14
|
5.34
|
0.03
|
0.08
|
-
|
Capex / Sales
|
260.79%
|
1,064.66%
|
441.13%
|
1.8%
|
4.16%
|
-
|
Announcement Date
|
9/23/18
|
9/25/19
|
9/29/20
|
8/29/21
|
9/30/22
|
10/26/23
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 11.49M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|